Trial record 1 of 1 for:    y-52-52120-145
Previous Study | Return to List | Next Study

Dysport® Adult Upper Limb Spasticity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01313299
Recruitment Status : Completed
First Posted : March 11, 2011
Results First Posted : October 23, 2015
Last Update Posted : March 7, 2017
Information provided by (Responsible Party):

Brief Summary:
The purpose of this research study is to assess the efficacy of Dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.

Condition or disease Intervention/treatment Phase
Nervous System Disorders Drug: Botulinum type A toxin (Dysport®) Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 243 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Multicentre, Prospective, Double Blind, Randomised, Placebo Controlled Study, Assessing the Efficacy and Safety of Dysport® Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury
Study Start Date : August 2011
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Dysport 500 U Drug: Botulinum type A toxin (Dysport®)
500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
Experimental: Dysport 1000 U Drug: Botulinum type A toxin (Dysport®)
1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
Placebo Comparator: Placebo Drug: Placebo
I.M. (in the muscle) injection on day 1 of a single treatment cycle.

Primary Outcome Measures :
  1. Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) [ Time Frame: From Baseline (Day 1) to Week 4 ]
    MAS scale is used to assess muscle tone using a 6-point scale where: 0=No increase in muscle tone, 1=Slight increase in muscle tone manifested by a catch and release or by minimal resistance at the end of the range of motion (ROM) when the part is flexed or extended, 1±Slight increase in muscle tone manifested by a catch followed by minimal resistance throughout the remainder of the ROM, 2=Marked increase in muscle tone through most of the ROM but affected part easily moved, 3=Considerable increase in muscle tone passive movement difficult or 4=Affected part(s) rigid in flexion or extension. The MAS has been derived for analyses as follows: 0=0 ; 1=1; 1+=2; 2=3; 3=4 and 4=5.

Secondary Outcome Measures :
  1. Physician's Global Assessment (PGA) of Treatment Response [ Time Frame: At Week 4 ]
    PGA is a 9-point scale used to assess global overall treatment response by the investigator (-4: markedly worse, -3: much worse, -2: worse, -1: slightly worse, 0: no change, +1: slightly improved, +2: improved, +3: much improved and +4: markedly improved).

  2. Change From Baseline in DAS Score for the Principal Target of Treatment (PTT) [ Time Frame: From Baseline (Day 1) to Week 4 ]

    DAS is a 4-point scale used to determine the extent of functional impairment in 4 functional domains (dressing, hygiene, limb position and pain). DAS scale rating: 0=No disability, 1=Mild disability (noticeable but does not interfere significantly with normal activities), 2=Moderate disability (normal activities require increased effort and/or assistance) and 3=Severe disability (normal activities limited).

    If subject chose 'Hygiene' as PTT the score collected will be between 0 and 3.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients - post stroke or brain injury
  • Modified Ashworth Scale ≥ 2
  • Ambulatory patients

Exclusion Criteria:

  • Previous treatment with botulinum toxin of any type within 4 months prior to study entry for any condition
  • Physiotherapy initiated less than 4 weeks before inclusion
  • Previous surgery, alcohol, phenol in upper limb
  • Neurological/neuromuscular disorders which may interfere with protocol evaluations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01313299

  Hide Study Locations
United States, California
Rancho Los Amigos National Rehabilitation Center
Downey, California, United States, 90242
United States, Connecticut
Associated Neurologist of Southern CT, PT
Fairfield, Connecticut, United States, 06824
United States, Florida
Parkinson's Disease & Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States, 33488
Design Neuroscience Miami
South Miami, Florida, United States, 33169
United States, Illinois
The Rehabilitation Institute of Chicago
Chicago, Illinois, United States, 60611
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029-6574
Weill Cornell Medical College
New York, New York, United States, 10065
United States, North Carolina
Univ of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Wake Forest Medical Center
Winston Salem, North Carolina, United States, 27157
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232
United States, Texas
University of Texas
Dallas, Texas, United States, 75080
Southwestern Medical Center at Dallas
Dallas, Texas, United States, 75390
University of North Texas HSC
Fort Worth, Texas, United States, 76104
University of Texas
Houston, Texas, United States, 77030
United States, Utah
University of Utah School of Medicine
Salt Lake City, Utah, United States, 84132
Université catholique de Louvain av Hippocrate 10
Bruxelles, Belgium
Clinique Universitaire
Yvoir, Belgium
Czech Republic
Neurologicka klinika, Olomouc
Olomouc, Czech Republic
Charles University in Prague
Praha 2, Czech Republic
Besançon, France
CHU Brest
Brest, France
Centre de Réadaptation de Coubert
Coubert, France
Centre Hospitalier Albert Chenevier-Hopital Henri Mondor
Créteil, France
Hopital Raymond Poincarré
Garches, France
Hôpital Sébastopol
Reims, France
CHU Strasbourg
Strasbourg, France
Hopital Rangueil
Toulouse, France
National Institut for Medical Rehabilitation
Budapest, Hungary
Petz Aladar County Hospital
Gyor, Hungary
University of Szeged
Szeged, Hungary
Azienda Hospedaliero
Catania, Italy
Policlinico Universitario Agostino Gemelli
Roma, Italy
Malopolskie Centrum Medyczne
Krakow, Poland
Krakowska Akademia Neurologii
Warszawa, Poland
Samodzielny Publiczny Centralny Szpital Kliniczny
Warszawa, Poland
Russian Federation
Medical Rehabilitation Center
Moscow, Russian Federation
Scientific Center of Neurology of RAMS
Moscow, Russian Federation
State University
St Petersburg, Russian Federation
Derer's Hospital
Bratislava, Slovakia
Univerzitna nemocnica Bratislava
Bratislava, Slovakia
Sponsors and Collaborators
Study Director: Ipsen Study Director Ipsen

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ipsen Identifier: NCT01313299     History of Changes
Other Study ID Numbers: Y-52-52120-145
2010-019069-28 ( EudraCT Number )
First Posted: March 11, 2011    Key Record Dates
Results First Posted: October 23, 2015
Last Update Posted: March 7, 2017
Last Verified: January 2017

Additional relevant MeSH terms:
Nervous System Diseases
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents